SEC Form 4 · accession 0001192482-18-000320
COLLEGIUM PHARMACEUTICAL, INC · COLL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Brannelly
Officer — Executive Vice President & CFO
Period of report
Jun 21, 2018
Accepted (ET)
Jun 22, 2018 · 6:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 21, 2018 | S | 5,100 | $27.50 | D | 128,336 | D | |
| Common StockF3 | Jun 21, 2018 | S | 4,900 | $28.35 | D | 123,436 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018.
- F2The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.80 to $27.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F3The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.84 to $28.55, inclusive.